Please login to the form below

Not currently logged in
Email:
Password:

Lidoderm

This page shows the latest Lidoderm news and features for those working in and with pharma, biotech and healthcare.

Endo builds pain management business

Endo builds pain management business

Endo also has an existing pain patch in the form of Lidoderm, which contains the active ingredient lidocaine.

Latest news

  • Endo agrees $1.6bn deal to buy Paladin Labs Endo agrees $1.6bn deal to buy Paladin Labs

    generic competition to Endo's Lidoderm (lidocaine) patch for post-shingles pain - and earnings per share (EPS) of $1.34, up from $1.28 a year earlier. ... Looking at the performance of Lidoderm, which fell 37 per cent, De Silva said that "prescription

  • Watson settles Lidoderm patent dispute with Endo Watson settles Lidoderm patent dispute with Endo

    Watson settles Lidoderm patent dispute with Endo. Watson can now bring its generic version of the post-shingles pain patch to US market two years early. ... Once another generic product is launched following the 2015 patent expiry, however, Watson will

  • Global survey shows neuropathic pain under-diagnosed and under-served

    Lidoderm is licensed to Endo for sale in the US and Versatis is licensed to Gruenenthal for the UK. ... For Endo in the US, Lidoderm racked up sales of USD 419 million in FY05.

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics